Meeting
2020 ASCO Virtual Scientific Program
A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors
Lara Dunn
Memorial Sloan Kettering Cancer Center, New York, NY
Lara Dunn , Alan Loh Ho , Juliana Eng , Loren S. Michel , James Vincent Fetten , Elizabeth Warner , Anuja Kriplani , Wanqing Iris Zhi , Kenneth K. Ng , Sofia Haque , David G. Pfister , Eric Jeffrey Sherman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03524326
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6541)
DOI
10.1200/JCO.2020.38.15_suppl.6541
Abstract #
6541
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
First Author: Antoine Desilets
Poster
2020 ASCO Virtual Scientific Program
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
First Author: Ulrich Keilholz
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman